Alamar Biosciences Completes $219.9M IPO, Including Full Over-Allotment Exercise

summarizeSummary

Alamar Biosciences announced the completion of its initial public offering, raising $219.9 million in gross proceeds, which includes the full exercise of the underwriters' over-allotment option.

check_boxKey Events

• IPO Successfully Completed

  The company completed its initial public offering on April 20, 2026, selling an aggregate of 12,937,500 shares of common stock at $17.00 per share.

• Substantial Capital Raised

  The IPO generated approximately $219.9 million in gross proceeds, before deducting underwriting discounts and estimated offering expenses.

• Underwriters' Over-Allotment Option Fully Exercised

  The total shares sold include the full exercise of the underwriters' option to purchase an additional 1,687,500 shares, indicating strong investor demand.

• Corporate Governance Established

  In connection with the IPO, the company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, establishing its public company governance structure, including authorization for 1,000,000,000 shares of common stock and 20,000,000 shares of preferred stock.

auto_awesomeAnalysis

Alamar Biosciences has successfully completed its initial public offering, raising approximately $219.9 million in gross proceeds. This amount is higher than the $191.25 million initially announced in the 424B4 filing on April 17, 2026, due to the underwriters fully exercising their option to purchase additional shares. The successful completion of the IPO, especially with strong demand leading to the full exercise of the over-allotment option, is a significant positive signal for the company, providing substantial capital for its operations. The stock is currently trading at $22.21, notably above its IPO price of $17.00, indicating a positive market reception. Concurrently, the company adopted new corporate governance documents, including an amended and restated certificate of incorporation and bylaws, which are standard procedures for a newly public company and establish its capital structure and operational framework.